Literature DB >> 6333556

Thoracic manifestations of the acquired immune deficiency syndrome.

H I Pass, D A Potter, A M Macher, C Reichert, J H Shelhammer, H Masur, F Ognibene, E Gelmann, H C Lane, A Fauci.   

Abstract

The acquired immune deficiency syndrome is characterized by the development of multiple recurrent opportunistic infections or unusual neoplasms in individuals with no prior history of immune suppression. This report summarizes the thoracic diseases encountered in such patients before after death and the role of diagnostic techniques currently used in the evaluation of thoracic disease in 15 patients with this syndrome. Efficacy of treatment was determined by correlation with postmortem findings in all patients. Pulmonary disease was present in all 15 patients and necessitated 23 transbronchial biopsies in 11 patients. Pneumocystis carinii pneumonia and cytomegalovirus pneumonia were the most common findings. Nine open lung biopsies in eight patients disclosed either Pneumocystis carinii pneumonia or Kaposi's sarcoma. Esophageal disease was present in four patients, and endoscopic evaluation demonstrated Candida esophagitis (two), esophageal Kaposi's sarcoma (one), and cytomegalovirus esophagitis and Kaposi's sarcoma (one). Mean time to death from diagnosis of acquired immune deficiency syndrome was 7.7 months, with respiratory insufficiency being the most common cause of death (9/15, 60%). Pneumocystis carinii pneumonia was successfully eradicated in 70% of the patients. Candida esophagitis was ameliorated in both patients with the disease. Unsuspected pulmonary Kaposi's sarcoma, cytomegalovirus pneumonitis, and other infectious pathogens were documented at autopsy. These data reveal that Pneumocystis carinii pneumonia and Candida esophagitis can be managed successfully in patients with acquired immune deficiency syndrome if appropriately diagnosed. The major cause of death in this series was pulmonary insufficiency, often the result of severe cytomegalovirus infection. Thoracic surgeons must continue to play an aggressive and important role in the early diagnosis and management of potentially treatable pulmonary and esophageal disease in these patients.

Entities:  

Mesh:

Year:  1984        PMID: 6333556

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Fibreoptic bronchoscopy in diagnosis of bronchopulmonary Kaposi's sarcoma.

Authors:  P J Hanson; J N Harcourt-Webster; B G Gazzard; J V Collins
Journal:  Thorax       Date:  1987-04       Impact factor: 9.139

2.  Murine cytomegalovirus-associated pneumonitis in the lungs free of the virus.

Authors:  K Tanaka; Y Koga; Y Y Lu; X Y Zhang; Y Wang; G Kimura; K Nomoto
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  Pulmonary Kaposi's sarcoma in Africa.

Authors:  A L Pozniak; A S Latif; P Neill; S Houston; K Chen; V Robertson
Journal:  Thorax       Date:  1992-09       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.